Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-K10 in adolescents and adults with moderate to severe asthma
CTR20244823Phase 3Active
- Sponsor
- Medigene AG
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of comekibart in asthma, sponsored by Medigene AG. Started Mar 2025; status: active.
02
Drugs
comekibart
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20244823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244823.